iBeta Quality Assurance (“iBeta”), a National Voluntary Laboratory Accreditation Program (NVLAP) accredited Biometrics Testing Laboratory, and DEA-approved EPCS Biometric Certification Lab has completed one of the first DEA EPCS biometric certifications for a series of fingerprint devices that can now officially be used in EPCS (Electronic Prescription of Controlled Substances) systems by prescribers of controlled substances in accordance with US DOJ DEA regulations. The biometric devices certified were the Lumidigm V-Series V3xx fingerprint readers. In addition to other regulations referenced in 21 CFR Parts 1311, iBeta determined that the four V3xx devices, when properly incorporated into an overall prescribing system, meet the required false match rate of 0.001.
iBeta’s Biometrics Team was very excited to work with Lumidigm. A global leader in authentication solutions, Lumidigm is dedicated to enabling convenient, secure, and reliable identification of people, products and credentials. Developed with “real world” performance as a priority, Lumidigm’s multispectral imaging technology, innovative software and biometric fingerprint sensors allow customers to know “who” or “what” to a high degree of certainty. Lumidigm and its strategic partners have met challenging authentication requirements in markets such as healthcare, banking, entertainment, and government services.
Kevin Wilson Ph.D., Principle Investigator on the Lumidigm V-Series certification project, stated, “The Lumidigm devices not only meet the DEA false match rate regulation, we encountered no failures to enroll during the certification test effort.
iBeta looks forward to continuing a strong working relationship with Lumidigm. iBeta’s Biometrics Team is available to perform testing on various biometric systems, devices and components.
The biometrics certification report of the Lumidigm V3xx devices is publicly available at iBeta Biometrics (http://www.ibeta.com/our-services/biometrics/epcs/reports).
